| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Ewan Pearson | Q56240082 |
| Clifford J Bailey | Q37842217 | ||
| P2093 | author name string | Laura J McCreight | |
| P2860 | cites work | Clinical Pharmacokinetics of Metformin | Q22241422 |
| Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase | Q22251079 | ||
| Metformin: its botanical background | Q22252857 | ||
| Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action | Q24613405 | ||
| Does apical membrane GLUT2 have a role in intestinal glucose uptake? | Q27023552 | ||
| The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing | Q27319522 | ||
| The SLC22 drug transporter family | Q28190073 | ||
| The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26 | Q28272232 | ||
| Effect of altered gastric emptying and gastrointestinal motility on metformin absorption | Q28344811 | ||
| The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. | Q50510276 | ||
| The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. | Q51298409 | ||
| The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. | Q51363916 | ||
| Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. | Q51364519 | ||
| Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. | Q51568639 | ||
| Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. | Q53083054 | ||
| Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: Stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? | Q62478786 | ||
| Alteration of bile acid metabolism and vitamin-B12-absorption in diabetics on biguanides | Q64984227 | ||
| Mechanism of metformin action in non-insulin-dependent diabetes | Q68950548 | ||
| Role of metformin accumulation in metformin-associated lactic acidosis | Q71733450 | ||
| Accumulation of metformin by tissues of the normal and diabetic mouse | Q72381698 | ||
| Lactic acidosis in patients with diabetes treated with metformin | Q74085124 | ||
| High and typical 18F-FDG bowel uptake in patients treated with metformin | Q81041182 | ||
| Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers | Q87240112 | ||
| Pharmacogenetic variation and metformin response | Q38170448 | ||
| A Comprehensive Review of Drug-Drug Interactions with Metformin | Q38460322 | ||
| Prediction and validation of enzyme and transporter off-targets for metformin. | Q38838317 | ||
| TGR5-mediated bile acid sensing controls glucose homeostasis | Q39805262 | ||
| Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells | Q40015373 | ||
| Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. | Q40237437 | ||
| Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. | Q40429191 | ||
| Clinical pharmacokinetics of metformin | Q41066472 | ||
| Metformin and cancer: Technical and clinical implications for FDG-PET imaging | Q41136911 | ||
| Effect of metformin on glucose metabolism in the splanchnic bed | Q41821318 | ||
| Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. | Q41985591 | ||
| Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors | Q42482872 | ||
| Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell | Q42495476 | ||
| Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin | Q42794766 | ||
| Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine | Q42803182 | ||
| 5-aminoimidazole-4-carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport: a possible role for AMPK. | Q42813833 | ||
| Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. | Q42837261 | ||
| Metformin-induced regulation of the intestinal D-glucose transporters. | Q42976856 | ||
| Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects | Q43566532 | ||
| Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect | Q44068560 | ||
| Effects of metformin on bile salt transport by monolayers of human intestinal Caco-2 cells | Q44198043 | ||
| Enhanced secretion of glucagon-like peptide 1 by biguanide compounds | Q44207056 | ||
| Differential effects of metformin on bile salt absorption from the jejunum and ileum | Q44358352 | ||
| Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. | Q44814545 | ||
| Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose | Q45423525 | ||
| Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. | Q45963267 | ||
| Metformin and the intestine | Q46557959 | ||
| Mechanisms underlying saturable intestinal absorption of metformin | Q46610955 | ||
| Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. | Q48243268 | ||
| The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study | Q28345534 | ||
| Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). | Q29473728 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| A metagenome-wide association study of gut microbiota in type 2 diabetes | Q29547726 | ||
| Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity | Q29615051 | ||
| Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. | Q30320847 | ||
| Importance of the intestine as a site of metformin-stimulated glucose utilization | Q30498794 | ||
| Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker | Q33678705 | ||
| Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis | Q33686783 | ||
| Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. | Q33838229 | ||
| Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands | Q34245062 | ||
| Effect of metformin on metabolic improvement and gut microbiota | Q34261321 | ||
| Gut metagenome in European women with normal, impaired and diabetic glucose control | Q34347521 | ||
| Identification and characterization of a novel monoamine transporter in the human brain | Q34353039 | ||
| Microbiota and diabetes: an evolving relationship. | Q34420231 | ||
| Interaction of organic cations with a newly identified plasma membrane monoamine transporter | Q34442849 | ||
| Metformin kinetics in healthy subjects and in patients with diabetes mellitus | Q34449285 | ||
| Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q34457919 | ||
| Gut Microbiota and Metabolic Disorders | Q34482945 | ||
| Traditional plant medicines as treatments for diabetes | Q34675107 | ||
| An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice | Q34785134 | ||
| Molecular imaging of cancer with positron emission tomography | Q34810431 | ||
| Human gut microbiota changes reveal the progression of glucose intolerance | Q34980773 | ||
| Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers | Q35156413 | ||
| GLUT2 accumulation in enterocyte apical and intracellular membranes: a study in morbidly obese human subjects and ob/ob and high fat-fed mice | Q35227156 | ||
| Metformin in patients with type 2 diabetes and kidney disease: a systematic review | Q35533239 | ||
| Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels | Q35584944 | ||
| Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion | Q35612377 | ||
| Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. | Q35675566 | ||
| Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota | Q35860108 | ||
| Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. | Q37027044 | ||
| Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine | Q37168725 | ||
| Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study | Q37193773 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | human digestive system | Q9649 |
| metformin | Q19484 | ||
| amidines | Q423088 | ||
| P304 | page(s) | 426-435 | |
| P577 | publication date | 2016-01-16 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Metformin and the gastrointestinal tract | |
| P478 | volume | 59 |
| Q33626631 | 18F-FDG uptake in the colon is modulated by metformin but not associated with core body temperature and energy expenditure |
| Q48004902 | 60 years of metformin use: a glance at the past and a look to the future |
| Q38647178 | A Structural Basis for Biguanide Activity. |
| Q90730557 | A Unique Case of Metformin-Associated Lactic Acidosis |
| Q94553285 | A Unique Case of Metformin-associated Severe Lactic Acidosis Without Preexisting Renal Disease: Perspectives on Prolonged Dialysis and Education for Prevention |
| Q64939000 | A Western diet-induced mouse model reveals a possible mechanism by which metformin decreases obesity. |
| Q89360925 | A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes |
| Q38670844 | A phase Ib study of everolimus combined with metformin for patients with advanced cancer |
| Q47240106 | A reappraisal on metformin |
| Q55516148 | Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. |
| Q64229319 | Allele Frequency of Met420del Metformin Main Transporter Encoding Gene among Javanese-Indonesian Population |
| Q58691643 | Association of metformin administration with gut microbiome dysbiosis in healthy volunteers |
| Q37622726 | Berberine Attenuates Intestinal Mucosal Barrier Dysfunction in Type 2 Diabetic Rats |
| Q90555954 | Bi-directional drug-microbiome interactions of anti-diabetics |
| Q37456235 | Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. |
| Q92855414 | Can Epigenetics of Endothelial Dysfunction Represent the Key to Precision Medicine in Type 2 Diabetes Mellitus? |
| Q48022106 | Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus |
| Q38945649 | Combatting type 2 diabetes by turning up the heat |
| Q38968961 | Could metformin be used in patients with diabetes and advanced chronic kidney disease? |
| Q64921468 | Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus. |
| Q33624480 | Delphinidin Reduces Glucose Uptake in Mice Jejunal Tissue and Human Intestinal Cells Lines through FFA1/GPR40. |
| Q90224362 | Diabetes: Is There a Future for Pharmacogenomics Guided Treatment? |
| Q28279770 | Drug interventions for the treatment of obesity in children and adolescents |
| Q61815750 | Drug-induced diabetes type 2: In silico study involving class B GPCRs |
| Q64063469 | Effect of Metformin on Antipsychotic-Induced Metabolic Dysfunction: The Potential Role of Gut-Brain Axis |
| Q48205957 | Effect of Metformin on Glycemic Control in Patients with Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials |
| Q92836367 | Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects |
| Q43246916 | Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. |
| Q90176456 | Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review |
| Q92669279 | Effect of adriamycin combined with metformin on biological function of human tongue cancer SSC-15 cells |
| Q38948037 | Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
| Q55314889 | Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study. |
| Q64072115 | Effects of Drugs and Excipients on Hydration Status |
| Q53411897 | Genetic Variants in CPA6 and PRPF31 are Associated with Variation in Response to Metformin in Individuals with Type 2 Diabetes. |
| Q30400204 | Gut microbiome analysis of type 2 diabetic patients from the Chinese minority ethnic groups the Uygurs and Kazaks |
| Q98726635 | Gut microbiota and diabetes: From correlation to causality and mechanism |
| Q90034560 | Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease |
| Q89918634 | Gut microbiota: closely tied to the regulation of circadian clock in the development of type 2 diabetes mellitus |
| Q47304462 | Health benefits of late-onset metformin treatment every other week in mice |
| Q55472178 | High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome. |
| Q58754013 | Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochloride |
| Q41206250 | Identification of Flavin-Containing Monooxygenase 5 (FMO5) as a Regulator of Glucose Homeostasis and a Potential Sensor of Gut Bacteria |
| Q99711568 | Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury |
| Q57098309 | Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes |
| Q90433037 | Improving Dissolution and Cytotoxicity by Forming Multidrug Crystals |
| Q96110740 | Insights into the gut microbiota of Nigerian elderly with type 2 diabetes and non-diabetic elderly persons |
| Q98568605 | Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk"-genotyping and patient categorizations, do they matter? |
| Q94502600 | Lycium barbarum Polysaccharides Improve Testicular Spermatogenic Function in Streptozotocin-Induced Diabetic Rats |
| Q88969153 | Mapping of biguanide transporters in human fat cells and their impact on lipolysis |
| Q90301380 | Mechanisms of action of metformin with special reference to cardiovascular protection |
| Q59138235 | Metabolic Effects of Metformin in the Failing Heart |
| Q46295009 | Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice. |
| Q89879412 | Metformin Alleviates Left Ventricular Diastolic Dysfunction in a Rat Myocardial Ischemia Reperfusion Injury Model |
| Q55155260 | Metformin Inhibits Mouse Islet Insulin Secretion and Alters Intracellular Calcium in a Concentration-Dependent and Duration-Dependent Manner near the Circulating Range. |
| Q46362610 | Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug |
| Q95271395 | Metformin and Its Benefits for Various Diseases |
| Q89490717 | Metformin and cardiorenal outcomes in diabetes: A reappraisal |
| Q92857492 | Metformin as a host-directed therapeutic in tuberculosis: Is there a promise? |
| Q98945094 | Metformin decreases bacterial trimethylamine production and trimethylamine N-oxide levels in db/db mice |
| Q53563716 | Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. |
| Q39247550 | Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm. |
| Q45047162 | Metformin-associated lactic acidosis: Moving towards a new paradigm? |
| Q47202033 | Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial |
| Q60912832 | Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes |
| Q60939760 | Metformin: A Candidate Drug for Renal Diseases |
| Q39100209 | Metformin: New Preparations and Nonglycemic Benefits |
| Q38645273 | Metformin: clinical use in type 2 diabetes. |
| Q48004913 | Metformin: historical overview |
| Q89689470 | Novel Interventions for the Prevention of Preeclampsia |
| Q39172757 | Nutrient sensing pathways as therapeutic targets for healthy ageing |
| Q37673171 | Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users. |
| Q51320034 | Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. |
| Q37059366 | Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials |
| Q26775259 | Personalized medicine in diabetes: the role of 'omics' and biomarkers |
| Q28274686 | Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery |
| Q49850150 | Pharmacokinetics of metformin in patients with gastrointestinal intolerance |
| Q47696671 | Pharmacological management of type 2 diabetes: what's new in 2017? |
| Q59138314 | Pleiotropic Effects of Metformin on Cancer |
| Q64113046 | Poor short-term glycemic control in patients with type 2 diabetes impairs the intestinal mucosal barrier: a prospective, single-center, observational study |
| Q92807746 | Response: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes metab J 2019;43;276-86) |
| Q38780926 | Roles of the gut in the metabolic syndrome: an overview |
| Q41999356 | Severity of Gastrointestinal Side Effects of Metformin Tablet Compared to Metformin Capsule in Type 2 Diabetes Mellitus Patients |
| Q91952946 | Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects |
| Q40468370 | Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. |
| Q48508868 | Targeted intestinal delivery of incretin secretagogues-towards new diabetes and obesity therapies |
| Q99549054 | The Effects of Metformin on the Gut Microbiota of Patients with Type 2 Diabetes: A Two-Center, Quasi-Experimental Study |
| Q89943833 | The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases |
| Q89819674 | The Interplay between Immune System and Microbiota in Diabetes |
| Q47117670 | The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis |
| Q97529467 | The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus |
| Q55114052 | The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus. |
| Q38774623 | The Role of Gut-brain Axis in Regulating Glucose Metabolism After Acute Pancreatitis |
| Q48291159 | The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. |
| Q92289039 | The effect of cold atmospheric plasma on diabetes-induced enzyme glycation, oxidative stress, and inflammation; in vitro and in vivo |
| Q52552476 | The effects of metformin on gut microbiota and the immune system as research frontiers. |
| Q41353984 | The mechanisms of action of metformin |
| Q37715482 | The stress polarity pathway: AMPK 'GIV'-es protection against metabolic insults |
| Q30240030 | Understanding and overcoming metformin gastrointestinal intolerance. |
| Q92797743 | Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus |
| Q64248232 | Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus |
| Q33658321 | Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis. |
| Q37222650 | Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin |
| Q39446720 | Vascular complications in diabetes: old messages, new thoughts |
| Q92969166 | Vitamin B12 deficiency and the knowledge and practice of physicians regarding screening for vitamin B12 deficiency among type 2 diabetic patients on metformin in selected hospitals in Riyadh, Saudi Arabia |
| Q47127733 | Zinc transporters and insulin resistance: therapeutic implications for type 2 diabetes and metabolic disease. |
| Q54371986 | [What do they offer new oral antibiotics?]. |
Search more.